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In this study we describe the development of strain
BMX100, a new Escherichia coli K12 tester strain, derived
from MX100, a strain which was constructed for detection
of mutagens and for mechanistic studies of chemical
carcinogens. We demonstrate here that strain BMX100 can
be used for stable expression of human CYP1A2 or human
CYP1A2 fused to rat liver NADPH cytochrome P450
reductase. Mutagenicity of precarcinogens known to be
bioactlvated by CYP1A2, namely 2-aminoanthracene
(2-AA), aflatoxin Bl (AFB1) and 2-amino-3-methylimid-
azo[4,5-/)quinoline (IQ), could be detected. The mutagenic
activity of 2-AA using BMX100 expressing CYP1A2 alone
and hi combination with rat CYP reductase was respectively
10 and 20 times higher than in BMX 100 with the standard
metabolic activation system, rat liver S9 fraction. Further-
more, the mutagenicity of 2-AA could be nullified by
a-naphthoflavone, a known inhibitor of CYP1A2. IQ
responded equally ha BMX100 expressing the CYP1A2-
reductase fusion protein as compared with usage of rat
liver S9 fraction. Rat liver S9 fraction was much more
potent in generating a mutagenic response to AFB1 hi
BMX 100 than in the strain expressing human CYP1A2
alone or CYP1A2 fused to rat reductase. The results
described hi this study demonstrate that this new E.coli
strain can function as a human CYPlA2-competent pro-
karyotic mutagenicity test system and they seem to charac-
terize BMX100 as a strain of interest for studies to identify
individual human CYPs involved hi bioactivation and
bioinactivation reactions of putative genotoxins.
Introduction
Metabolism of chemical carcinogens plays a major role in the
aetiology of cancer (Gonzalez and Gelboin, 1994). A better
understanding of the properties of carcinogen metabolizing
enzymes will thus aid in studies of human risk assessment.
The majority of cell systems currently used for genotoxicity
assays are not competent for metabolism of xenobiotics or
they have lost this capacity (Miller and Miller, 1981;
Langenbach et al, 1992). These cell systems are therefore
often combined with an exogenous metabolic activation system,
usually a hepatic post-mitochondrial supernatant (S9).
Although the combination of metabolic activation systems
with these cell systems has contributed much to the success
of genotoxicity assays, application of metabolic activation
systems still has a number of drawbacks (Bridges and Hubbard,
1980; Langenbach et al, 1992). Since metabolic activation
occurs outside the target cell, the sensitivity for detection of
highly reactive, short-lived metabolic intermediates may be
limited. Furthermore, enzyme activities of these metabolic
activation systems are highly variable and usually constitute
varying concentrations of multiple (iso)enzymes, which make
it difficult to determine the relative contribution of individual
(iso)enzymes (Langenbach et al, 1992).
In order to overcome these drawbacks novel metabolically
competent cell systems for use in genotoxicity testing are
being developed (Gonzalez and Gelboin, 1994; Rueff et al.,
1996). One approach to determine the contribution of specific
mammalian (iso)enzymes in bio(in)activation of chemical
carcinogens is by heterologous expression of mammalian
cDNAs in the target cell (Gonzalez et al, 1991; Langenbach
et al., 1992). Using this approach for prokaryotic genotoxicity
assays a number of studies have been reported, e.g. for
glutathione S-transferase (GST) (Simula et al, 1993; Thier
et al, 1993), N-acetyltransferase (NAT) (Grant et al., 1992),
sulfotransferases (Glatt, 1997) and cytochrome P450 (CYP)
(Josephy et al, 1995).
Recently we reported on the construction of a new
Escherichia coli K12 genotoxicity tester strain MX 100, especi-
ally designed for the study of mechanistic aspects of genotoxic
carcinogens (Kranendonk et al, 1996). MX100 is sensitive to
a variety of mutagens, including oxidative mutagens, which
are monitored by back mutation to L-arginine prototrophy via
base substitution mutations. Since this strain is derived from
the well-known E.coli K12 laboratory strain AB1157, MX100
is a useful strain for development of specialized tester strains
in metabolic studies of chemical carcinogens, notably by
heterologous expression of specific mammalian drug
metabolizing enzymes (Kranendonk et al, 1996).
A prerequisite for the use of MX 100 and other cell systems
as a mammalian enzyme expressing cell system is that the cell
system itself is characterized for endogenous biotransformation
capabilities, as these could interfere with the bio(in)activation
activities of the expressed enzyme and might lead to incorrect
conclusions concerning the role of the expressed enzyme in
bio(in)activation of a chemical. A comprehensive characteriza-
tion of bioactivation and bioinactivation enzyme activities of
strain MX 100 has recently been performed (Kranendonk et al,
1997). MX100 demonstrated significant metabolic activities
of phase I enzymes (nitroreductase and DT-diaphorase), phase
II enzymes (GSTs, NATs and UDP-glucuronyl transferases),
phase III enzymes (cysteine conjugating (J-lyase) and anti-
oxidant enzymes (superoxide dismutase, catalase, glutathione
reductase and alkyl hydroperoxide reductase) and it contained
appreciable levels of glutathione (GSH). Furthermore, a sig-
nificant NADPH-flavodoxin:oxidoreductase activity was
detected in MX 100. It has been reported that this enzyme
is able to support the activity of heterologously expressed
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mammalian CYPs (Jenkins and Waterman, 1994). CYP is
considered to be the most important phase I biotransformation
enzyme involved in bioactivation of chemical carcinogens
(Gonzalez and Gelboin, 1994, Goeptar et al, 1995).
We report here on the construction of a novel tester strain
BMX100, a derivative of strain MX 100, designed for stable
heterologous expression of mammalian metabolic enzymes.
We demonstrate here that BMX100 can actively express human
CYP1A2 alone or as a fusion with rat liver NADPH CYP
reductase and that it demonstrates sensitive mutagenic
responses towards specific precarcinogens.
Materials and methods
Reagents and enzymes
4-Nitroquinoline-l-oxide (4NQO), L-arginine, aflatoxin Bl (AFBI),
2-aminoathracene (2-AA), ot-naphthoflavone (oc-NF), isopropylthiogalactoside
(IPTG), ATP and thiamine were obtained from Sigma Chemical Co. (St
Louis, MO). Ampicillin (sodium salt) was from Northumbria Biologicals
(Northumberland, UK). Bacto agar, bacto tryptone, bacto yeast extract and
bacto peptone were from Difco (Detroit, MI). The antibiotic kanamycin
sulphate was obtained from Boenngher-Mannheim (Mannheim, Germany).
Restriction enzymes BamHl, Pstl and Accl were obtained from Stralagene
(La Jolla, CA) and T4 DNA ligase from Promega (Madison, WI). Plasmid
pACYC 177 was obtained from New England Biolabs (Beverly, MA). 2-Amino-
3-methylimidazo[4,5-/]quinoline (IQ) was a generous gift of Dr Gnvas
(Swedish University of Agriculture Sciences, Uppsala, Sweden).
Strains and plasmids
A new mutator plasmid was constructed to circumvent plasmid incompatibility.
The mucAB operon was excised from plasmid pGW270 (Langer et al., 1981)
as a 2.5 kb Pst\—Accl fragment and subcloned into pUC18, previously digested
with Pstl and Accl. Plasmid DNA was transfected into DH5a cells by the
CaClj method (Sambrook et al, 1989). A clone was selected and plasmid
DNA of this new plasmid (pHCM) was isolated. Subsequently, the mucAB
operon was excised from pHCM as a 3.1 kb BamHl-Pstl fragment and cloned
in plasmid pACYC177 (Chang.A.C.Y and Cohen, 1978), previously digested
with BamHl and Pstl. Plasmid DNA was transfected into XL 1-blue Epicunan
Coli competent cells (Stratagene) by the procedure described by the manufac-
turer. The new plasmid (pLCM) was isolated and transfected into strain
FP401, the mother strain of the E.coli K12 tester strain MXI00 (Kranendonk
et al, 1996), by the CaCl2 method and selected for kanamycin-resistant
growth. The new strain was designated BMX100.
Plasmids pCWori + , containing the modified human CYP1A2 sequence
(Fisher et al., 1992), and pCWon + , containing the modified human CYP1A2
sequence fused to the rat NADPH CYP reductase sequence (Shet et al., 1995),
were transfected into BMX100 by the CaCl2 method, resulting in strains
BMXI00/hlA2 and BMX100/hlA2-rRed respectively. Both plasmids were a
generous gift of Dr Fisher and Prof. Estabrook (Southwestern Medical Center.
University of Texas, Dallas, TX).
Analysis of CYP expression
Expression of CYP in bacteria was analysed spectrophotometrically (difference
spectrum, reduced-carbon monoxide versus reduced) as previously described,
with minor modifications (Rutten et al., 1987) Cultures of BMX100/hlA2
and BMX10Q/hlA2-rRed, grown as described below, were centrifuged at
2600 g for 15 min at 4°C. Bacterial pellets were resuspended in the same
volume of TN buffer (50 mM Tns, 0.85% NaCl. pH 7.5). Spectra were
recorded using a Pye Unicam SP8-100 UV/VIS speclrophotometer
Mutagenicity assays
Strains BMX100/hlA2 and BMX100/hlA2-rRed were cultured as previously
described with minor modifications (Fisher et al.. 1992) Bacteria were grown
for 18 h in TB medium supplemented with peptone (2 g/1), ampicillin (50 (ig/
ml), kanamycin (15 |ig/ml), thiamine (1 Jlg/ml), a mixture of trace elements
(0.4 ml/1) (Bauer and Shiloach, 1974) and IPTG (1 mM) as appropriate at
29°C. Hepatic post-mitochondnal supernatant (S9) of male Wistar rats, induced
with Aroclor 1254. was prepared as previously described (Maron and Ames.
1983) and applied in the standardized 10% mix (Maron and Ames, 1983) in
the mutagenicity assays
The mutagenicity assays with strains BMX100/hlA2 and BMX100/hlA2-
rRed were performed using the liquid preincubation assay technique as
described by Maron and Ames (1983). with minor modifications Preincubation
was performed for 45 min in an orbital shaker at 37°C. before plating.
Incubation buffer contained 10 mM glucose. The inhibition study with
a-naphthoflavone (a-NF) was performed with a 15 min incubation at 37°C
with bacteria and inhibitor in buffer, prior to addition of the carcinogen.
Experiments were performed at least in triplicate. Revertant colonies were
counted after the normal 48 h incubation at 37°C. Mutagenic activities (in
revertants/nmol carcinogen) were determined from the slope as the least
square line of the linear portion of the dose-response curve.
Results
The E.coli K12 tester strain MX 100 has been developed for
detection of mutagens and characterized as a strain of interest
for mechanistic studies of chemical carcinogens (Kranendonk
et al, 1996; 1997). No CYP activity could be detected in
strain MX100. This strain could therefore be applied as a
heterologous expression system for CYPs. When plasmid
pCWori+ containing the modified cDNA of human CYP1A2
(pCWori/hlA2) (Fisher et al, 1992) was introduced into
MX 100 we found low and unstable expression of CYP and
no detectable bioactivation activity for AFBI and 2-AA, two
compounds used as model genotoxins (data not shown). Strain
MX 100 contains the SOS mutagenesis plasmid pKRll, which
is maintained at low copy number (Kranendonk et al, 1994a,
1996). This plasmid is a deletion derivative of the standard
mutator plasmid pKM 101 (Langer et al, 1981), which contains
a ColE 1 -type replicon (Langer et al., 1985). Plasmid pCWori +,
a derivative of plasmid pHSe5, is a pBR322-derived plasmid
and thus contains the pMBl origin of replication (Browner
et al, 1991; Fisher et al, 1992). High plasmid instability
occurs when both plasmids are transferred to the same bacteria]
cell, a phenomenon known as plasmid incompatibility
(Sambrook et al, 1989), which was verified in MX100 when
transformed with pCWori + .
Strain BMX100
The relevant sequences of plasmid pKRll necessary for
mutagenicity testing, the mucAB operon (Kranendonk et al,
1994a), were cloned in pACYC177 (Chang,A.C.Y. and Cohen,
1978), to circumvent plasmid incompatibility of pKRll and
pCWori+ in MX 100. pACYC177 is maintained at low copy
number and contains replicon pi5A, a replicon compatible
with the ColEl origin (Sambrook et al, 1989). The newly
constructed plasmid (pLCM) was introduced into the mother
strain of MX 100, FP401, resulting in strain BMX100. The
efficiency of mutagen detection of strain BMX100 was
checked, relative to strain MX 100, with three diagnostic
mutagens, namely 4NQO, benzo[a]pyrene (B[a]P) and AFBI,
the last mutagens with the rat liver S9 fraction (see Figure 1).
Results obtained with these carcinogens demonstrated that
BMX100 responds similarly to MX100. Plasmid pCWori + ,
containing the modified cDNA of human CYP1A2, was
subsequently introduced into strain BMX100, designated
BMX100/hlA2.
Expression of human CYP1A2 in strain BMX100
Expression of human CYP1A2 in strain BMX100 was detected
by opticaJ difference spectrophotometry. When expression in
strain BMX100/hlA2 was induced with 1 mM IPTG a CYP
difference spectrum could be recorded, as illustrated in Figure
2a. The typical 449 nm absorbance maximum of the difference
spectrum of CYP1A2 is present, as demonstrated previously
in E.coli (Fisher et al, 1992). Without IPTG strain BMX100/
hlA2 demonstrated spectra as shown in Figure 2b, with
absorbance minima at 444 and 430 nm and an absorbance
maximum at 416 nm, which are characteristic for the bacterial






















Fig. 1. Histograms of the mutagenic activity of 4NQO, B[a]P and AFBl in strains MX100 (open blocks) and BMXIOO (hatched blocks). B[a]P and AFBl
were tested with the standard 10% rat liver S9 mix. Bars, standard deviation.
Mutagenicity of 2-aminoanthracene in strains BMX100/hlA2
and BMX100/hlA2-rRed
When strain BMX100/hlA2, expressing CYP1A2, was used
in a mutagenicity assay 2-AA showed a dose-dependent
increase in mutagenicity (see Figure 3) with a mutagenic
activity (revertants/nmol) 10 times higher than obtained with
the traditional rat liver S9 fraction (see inset of Figure 3
and Table I). Another expression vector was subsequently
introduced into strain BMXIOO, namely pCWori+, containing
the modified cDNA of human CYP1A2 fused to cDNA of rat
liver NADPH CYP reductase (pCWori/h 1 A2-rRed) (Shet etal,
1995), resulting in strain BMX100/hlA2-rRed. The level of
CYP expression in this strain was approximately one third of
that measured for BMX100/hlA2. 2-AA demonstrated a 20-
fold increase in mutagenic activity in strain BMX100/hlA2-
rRed as compared with rat liver S9 (Figure 3 and Table I). No
mutagenicity could be detected for 2-AA in strain BMX100/
hlA2 without induction, as shown in Figure 3.
The mutagenicity of 2-AA in the induced strain BMX100/
hlA2-rRed could be inhibited to background levels by
a-naphthoflavone, a specific inhibitor of the CYP1A family
(Chang,T.K.H. etal., 1994), at a dose of 1 nmol/plate (Figure 4).
Mutagenicity of AFBl and IQ in strains BMX100/1A2 and
BMX100/hlA2-rRed
We also tested AFBl in strain BMX100/hlA2 (Table I) as
well as AFBl and IQ in strain BMX100/hlA2-rRed (Figures
5 and 6 respectively). AFB1 demonstrated a mutagenic activity
in strain BMX100/1A2 (Table I) which was increased by a
factor of ~5 in strain BMX100/hlA2-rRed. (see Figure 5 and
Table I). The mutagenic activity of AFBl was substantially
higher in BMXIOO using the rat liver S9 fraction than in
BMXIOO expressing human CYP1A2 or in BMXIOO
expressing CYPlA2-reductase fusion protein (see Figure 5
and Table I). AFBl showed no mutagenicity in BMXIOO when
CYP expression was not induced, as shown in Figure 5.
IQ was only tested in strain BMX100/hlA2-rRed and
showed a mutagenicity similar to that obtained with the rat
liver S9 fraction (Figure 6 and Table I). As previously shown
for other carcinogens, no mutagenicity was detected for IQ
when CYP expression was not induced in BMX100/hlA2-
rRed.
Discussion
A number of approaches are available to assess the role of
drug and xenobiotic metabolizing enzymes in activation and/or
inactivation of chemicals that might act as potential carcinogens
(Miles and Wolf, 1991). Heterologous expression of human
enzymes in a cell system used for mutagenicity testing has the
advantage that metabolites are generated inside the target cell
and thus enable study of the role of a single gene product in
bio(in)activation of chemicals.
CYPs mediate major routes in bioactivation of chemical
carcinogens (Guengerich, 1992; Gonzalez and Gelboin, 1994).
In this study we report on the development of a new E.coli
tester strain, BMXIOO, which is able to express active human
CYP1A2, alone or fused to rat liver NADPH CYP reductase.
With these strains we were able to detect bioactivation of
2-AA, AFBl and IQ. These three precarcinogens are known
to become more genotoxic following oxidative metabolism
catalysed by CYP1A2 (Gonzalez and Korzekwa, 1994).
2-AA demonstrated a 10-fold higher mutagenic activity in
strain BMXIOO expressing human CYP1A2 than in BMXIOO
with the standard rat liver S9 fraction (Table I). This mutagenic
activity was increased ~2-fold when tested in BMXIOO
expressing human CYP1A2 fused to rat liver NADPH CYP
reductase. Furthermore, the mutagenicity of 2-AA could be
nullified by a-naphthoflavone, a known inhibitor of the CYP1A
family (Chang.T.K.H. et al, 1994), confirming the bioactiv-
ation capacity of human CYP1A2 expressed in BMXIOO.
Aromatic amines, like 2-AA, are activated by /V-hydroxylation
and subsequent O-acetylation mediated by CYP1A2 and NAT
respectively (Gonzalez and Gelboin, 1994). As previously
shown, strain MX100 contains a bacterial NAT activity
(Kranendonk et al., 1997). This activity is probably responsible
for the observed mutagenicity of 2-AA in BMX100/hlA2 and
BMX100/hlA2-rRed.
The potent hepatocarcinogen AFBl demonstrated a muta-
genic response when tested in strain BMXIOO, expressing
human CYP1A2 alone, which is increased ~5-fold when the
strain contained CYP1A2 fused to rat NADPH CYP reductase
(Table I). Both these mutagenic activities were substantially
lower than the activity in BMXIOO supported by rat liver S9
fraction. AFB 1 is activated by CYP to the ultimate carcinogen,
AFBl-8,9-epoxide (Eaton and Gallagher, 1994). Multiple
forms of CYP seem to be involved in metabolism of AFB 1
and at least five isoforms are able to activate this carcinogen
(Aoyama et al., 1990). CYP1A2 and 3A4 are considered to
be the more important isoforms (Crespi et al, 1991; Gallagher
et al, 1994). Furthermore, it has been previously shown that
there is a marked species difference in bioactivation of AFB 1
between rat and human (Ramsdell and Eaton, 1990). Rat liver
microsomes are far more efficient in generating AFB 1-8,9-
epoxide than human liver microsomes. This fact could, in part,
explain the higher mutagenic activity observed with rat liver
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Fig. 2. Fe2 +-CO versus Fe2+ difference spectra of bacteria of strain
BMX10Q/hlA2 in which expression of human CYP1A2 was induced (upper
panel) or not induced (lower panel). The spectra shown in the upper panel
indicate expression of 209 nmol P450 per liter of culture.
many other CYP isoforms which are involved in bioactivation
of A r a l .
The heterocyclic aromatic amine IQ, a potent food carcino-
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Fig. 3. Mutagenicity of 2-AA in strain BMX100 with the two expression
vectors for human CYP1A2. hlA2, strain BMX100 containing the
expression vector with cDNA of human CYP1A2; hlA2-rRed, strain
BMX100 containing the expression vector with cDNA of human CYP IA2
fused to cDNA of rat liver NADPH CYP reductase; +, induction of
expression witJi I mM IPTG; - . no induction of expression, points, mean of
at least triplicate determinations, bars, standard deviation. For inset S9,
standard (10%) rat liver S9 mix.
expressing human CYP1A2 fused to rat CYP reductase. This
mutagenicity in BMXIOO/hl A2-rRed was similar to that found
for BMX100 supported by the rat liver S9 fraction. IQ is
metabolized by CYP1A2 to its hydroxylamine, but ester
formation, in which acetyltransferase and sulfotransferase are
thought to be of importance, is believed to be necessary for
production of the ultimate carcinogen (Kadlubar el al., 1992).
As mentioned before, acetyltransferase activity was demon-
strated in strain MX 100, but no sulfotransferase activity could
be detected (Kranendonk et al., 1997). This seems to imply a
role of bacterial NAT in the bioactivation of IQ described in
this study.
IQ was ~ 10-fold less mutagenic in strain BMX100/hlA2-
rRed than 2-AA (Table I). Bioactivation of 2-AA and IQ has
previously been described in the Salmonella typhimurium
Umu-test with use of an exogenous metabolic system, derived
from E.coli membranes containing human CYP1A2 (Shimada
et al., 1994). The Salmonella tester strain used also contained
an increased level of bacterial NAT. 2-AA and IQ demonstrated
considerable but similar HWM-inducing capacities in this test.
The difference in mutagenicity for IQ in the two systems could
be due to limiting NAT activity in BMX100, although this is
not reflected in our results for 2-AA. Furthermore, bioactivated
IQ intermediates could have similar «ww-inducing capacities
but be less efficient in inducing arginine reversion in BMX100
as compared with bioactivated 2-AA.
Strain BMX100/hlA2 showed a 3-fold higher CYP1A2
expression level as compared with strain BMXIOO/hl A2-rRed.
Mutagenic activities were therefore normalized (in revertants/
nmol.pmol CYP) for the plated (expressed) amount of CYP.
to correctly compare the two strains for bioactivation (Table
I). 2-AA was approximately seven times more effectively
bioactivated when using the system containing human CYP1A2
 at V
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Expression of human cytochrome P450 1A2 in E.coli
Table I. Mutagenic activities of three carcinogens in
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Mutagenic activities are expressed as revertants/nmol carcinogen ± SD and normalized for the plated amount of cytochrome P450 as revertants/nmol
carcinogen/pmol P450 ± SD.
hlA2, expression vector with cDNA of human P450 1A2; hi A2-rRed, expression vector with cDNA of human P450 1A2 fused to cDNA of rat liver NADPH
P450 reductase; S9, standard (10%) rat liver S9 mix.
"Determined with strain BMX100/hlA2 without induction of expression.
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Fig. 4. a-Naphthoflavone inhibition of 2-AA mutagenicity in strain
BMX100/hlA2-rRed with induction. Data are represented as a percentage
of the control response (0.41 nmol 2-AA, 1519 revertants/plate). Points,
mean of at least triplicate determinations; bars, standard deviation.
fused to rat CYP reductase as compared with the system
containing CYP1A2 alone. For AFB1 this increase was ~14
times. The difference in increase is probably due to the fact
that AFB1 is bioactivated in a single CYPlA2-mediated
reaction as compared with 2-AA, which, besides the CYP1A2-
mediated step, needs a subsequent phase II reaction to become
mutagenic, as described above.
We have previously reported on the detection of NADPH
flavodoxin reductase in strain MX 100 (Kranendonk et al,
1997), a bacterial reductase which has been shown to be able
to support mammalian CYP activity, albeit at a very slow rate
(Jenkins and Waterman, 1994). This enzyme is probably
responsible for the observed activation activities of human
CYP1A2 in strain BMXIOO when expressed without rat
NADPH CYP reductase. The mutagenic activity of 2-AA in
BMXIOO expressing CYP1A2 alone and in combination with
rat CYP reductase was respectively 10 and 20 times higher
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Fig. 5. Mutagenicity of AFB1 in strain BMXIOO containing the expression
vector with cDNA of human CYP1A2 fused to cDNA of rat liver NADPH
P450 reductase. For an explanation of symbols used see Figure 2. Points,
mean of at least triplicate determinations; bars, standard deviation.
knowledge this is the first time that mutagenicity is more
effectively detected in a CYP-competent prokaryotic test
system relative to using the rat liver S9 fraction with a non-
competent prokaryotic system. These results confirm the notion
that the usage of metabolically competent test systems can be
more efficient in detection of mutagens relative to usage of
exogenous metabolic systems, due to the extracellular genera-
tion of reactive metabolites.
In the last decade a number of heterologous expression
systems, e.g. in bacteria, yeast, mammalian and insect cells,
have been developed for mammalian CYPs and used for various
types of studies (for reviews see Gonzalez and Korzekwa, 1994;
Waterman, 1994). Some of these systems have been used to
design CYP competent mutagenicity test systems, predomin-
antly in mammalian cells (Gonzalez and Gelboin, 1994). The
highest expression levels of mammalian CYPs were obtained
in bacteria, namely in E.coli (Gonzalez and Korzekwa, 1994).
Specific E.coli expression vectors were used and minor
N-terminal modifications of the CYPs had to be made to
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Fig. 6. Mutagenicity of IQ in strain BMXIOO containing the expression
vector with cDNA of human CYP1A2 fused to cDNA of rat liver NADPH
P450 reductase. For an explanation of symbols used see Figure 2 Points,
mean of at least triplicate determinations; bars, standard deviation
used in this study. The majority of these expression vectors
are based on Lad repression, by which controllable expression
of CYP can be obtained in E.coli. Due to the medium/high
copy number of these plasmids, it is necessary that these
vectors are introduced in a strain with a high LacI background
(like strains JM105 and DH5a) or that the vector itself encodes
for highly expressed E.coli Lacfi (such as the pCWori +
vector). As pointed out by us previously (Kranendonk et al,
1994b), an E.coli tester strain seems to be more appropriate
for heterologous expression with the above described E.coli
vectors, as S.typhimurium lacks the lac operon and expression
from these vectors was optimized for use in E.coli. Repression,
and therefore controllability, of expression can be lost when
mammalian metabolic enzymes are introduced into S.typhi-
murium tester strains with this type of E.coli vector. This has
been shown for example for human GST (Simula et al, 1993;
Thier et al, 1993; Oda et al, 1996), human NAT (Grant et al,
1992) and human CYP (Josephy et al, 1995). Complete
repression of expression of human CYP1A2 in strains
BMX100/hlA2 and BMXIOO/hl A2-rREd seems to occur cor-
rectly, as no mutagenicity is observed for 2-AA, AFB1 and
IQ and no CYP could be detected by spectrophotometric
methods without induction. These results corroborate a pre-
vious study in which it was demonstrated that MX 100 is
devoid of CYP activities (Kranendonk et al, 1997).
In conclusion, we have demonstrated here that strain
BMXIOO can be used for controllable heterologous expression
of human CYP1A2 and can function as a human CYP1A2-
competent prokaryotic mutagenicity test system in which
bioactivation can be detected for precarcinogens known to be
activated by CYP1A2. MX 100, the mother strain of BMXIOO,
has recently been comprehensively characterized for >20
endogenous biotransformation capabilities, so as to avoid
incorrect conclusions concerning the role of heterologous
expressed enzymes as well as to determine bacterial enzymes
and factors which could function as accessory enzymes, such
as NADPH flavodoxin reductase (Kranendonk et al, 1997).
In a previous study the activities of the major phase II enzymes
were determined. Some of these activities are of importance
for mutagenicity of chemical carcinogens in BMXIOO as
described here for 2-AA and IQ. However, precarcinogens
other than 2-AA and IQ could require different phase II
activities for bioactivation. Currently further characterization of
strain BMXIOO expressing human CYP1A2 is being performed
with premutagens known to be bioactivated by CYP but by
others then 1A2.
Since most research in this area is ultimately directed
towards risk assessment of human exposure, there is an
inherent advantage to using human enzymes. Strain BMXIOO
is apparently appropriate for expression of individual human
CYP enzymes involved in bioactivation and bioinactivation
reactions. At the moment other human CYP isoforms are being
expressed in strain BMXIOO and tested with different classes
of precarcinogens.
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